Hormel Foods vs Danone SA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hormel Foods Corporation (HRL)

Q3 202628 Jul – 3 Oct 2026

▲2▼1

Hormel's profit holds up but sales shrink; new CEO bets $1B on chicken

Sales keep shrinking and guidance was cut Hormel's quarterly sales fell 2.4% to $2.96 billion and missed forecasts, with volumes down 7.4%. Management cut its full-year sales outlook to about $12.1-12.2 billion, citing cautious shoppers, weak nut sales and high freight costs. Falling sales and a weaker top line pull the stock down.
The revenue miss and lowered sales guidance are the core reason the stock fell this period.
Profits beat and profit outlook was raised Even with weaker sales, Hormel earned $0.37 a share, beating estimates, and raised the bottom of its full-year profit guidance to $1.45-$1.51. Cost cuts, including an 18% drop in advertising, lifted adjusted operating margin to 9.0% from 8.4%. Better profits support the stock.
This is the main counterweight: earnings and margins improved even as sales fell.
$1.055 billion deal to buy chicken maker Brakebush Hormel agreed to buy Brakebush Brothers, a value-added chicken company with about $1.2 billion in yearly sales, for roughly $1.055 billion. The deal should add to earnings per share from fiscal 2028 and strengthens its Foodservice business, its best-performing unit. Investors see growth ahead.
This is the biggest new strategic move of the period and a clear positive for future growth.
New CEO and CFO take over as Hormel reshapes its portfolio John Ghingo becomes CEO on October 26 and Ash Bhumbla, formerly of Tyson Foods, is the new CFO. Both arrive as Hormel sells its Brazil operations and exits some private-label snack nuts. New leadership could sharpen execution, but the direction is unproven, so the market waits and sees.
Leadership changes and portfolio reshaping are a major force behind Hormel's story this period.

August 202628 Jul – 3 Oct 2026

▲2▼1

Hormel's profit holds up but sales shrink; new CEO bets $1B on chicken

Sales keep shrinking and guidance was cut Hormel's quarterly sales fell 2.4% to $2.96 billion and missed forecasts, with volumes down 7.4%. Management cut its full-year sales outlook to about $12.1-12.2 billion, citing cautious shoppers, weak nut sales and high freight costs. Falling sales and a weaker top line pull the stock down.
The revenue miss and lowered sales guidance are the core reason the stock fell this period.
Profits beat and profit outlook was raised Even with weaker sales, Hormel earned $0.37 a share, beating estimates, and raised the bottom of its full-year profit guidance to $1.45-$1.51. Cost cuts, including an 18% drop in advertising, lifted adjusted operating margin to 9.0% from 8.4%. Better profits support the stock.
This is the main counterweight: earnings and margins improved even as sales fell.
$1.055 billion deal to buy chicken maker Brakebush Hormel agreed to buy Brakebush Brothers, a value-added chicken company with about $1.2 billion in yearly sales, for roughly $1.055 billion. The deal should add to earnings per share from fiscal 2028 and strengthens its Foodservice business, its best-performing unit. Investors see growth ahead.
This is the biggest new strategic move of the period and a clear positive for future growth.
New CEO and CFO take over as Hormel reshapes its portfolio John Ghingo becomes CEO on October 26 and Ash Bhumbla, formerly of Tyson Foods, is the new CFO. Both arrive as Hormel sells its Brazil operations and exits some private-label snack nuts. New leadership could sharpen execution, but the direction is unproven, so the market waits and sees.
Leadership changes and portfolio reshaping are a major force behind Hormel's story this period.

Latest28 Jul – 3 Oct 2026

▲2▼1

Hormel's profit holds up but sales shrink; new CEO bets $1B on chicken

Sales keep shrinking and guidance was cut Hormel's quarterly sales fell 2.4% to $2.96 billion and missed forecasts, with volumes down 7.4%. Management cut its full-year sales outlook to about $12.1-12.2 billion, citing cautious shoppers, weak nut sales and high freight costs. Falling sales and a weaker top line pull the stock down.
The revenue miss and lowered sales guidance are the core reason the stock fell this period.
Profits beat and profit outlook was raised Even with weaker sales, Hormel earned $0.37 a share, beating estimates, and raised the bottom of its full-year profit guidance to $1.45-$1.51. Cost cuts, including an 18% drop in advertising, lifted adjusted operating margin to 9.0% from 8.4%. Better profits support the stock.
This is the main counterweight: earnings and margins improved even as sales fell.
$1.055 billion deal to buy chicken maker Brakebush Hormel agreed to buy Brakebush Brothers, a value-added chicken company with about $1.2 billion in yearly sales, for roughly $1.055 billion. The deal should add to earnings per share from fiscal 2028 and strengthens its Foodservice business, its best-performing unit. Investors see growth ahead.
This is the biggest new strategic move of the period and a clear positive for future growth.
New CEO and CFO take over as Hormel reshapes its portfolio John Ghingo becomes CEO on October 26 and Ash Bhumbla, formerly of Tyson Foods, is the new CFO. Both arrive as Hormel sells its Brazil operations and exits some private-label snack nuts. New leadership could sharpen execution, but the direction is unproven, so the market waits and sees.
Leadership changes and portfolio reshaping are a major force behind Hormel's story this period.

Danone SA (BN.PA)

Q3 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

July 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

Latest22 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.